| 8.23 0.31 (3.91%) | 11-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.69 | 1-year : | 13.1 |
| Resists | First : | 9.15 | Second : | 11.22 |
| Pivot price | 7.24  |
|||
| Supports | First : | 5.82 | Second : | 4.84 |
| MAs | MA(5) : | 7.17 |
MA(20) : | 7.77 |
| MA(100) : | 9.01 |
MA(250) : | 13.84 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 56.4 |
D(3) : | 36.4 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 46.79 | Low : | 3.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALGS ] has closed below upper band by 11.9%. Bollinger Bands are 0.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.59 - 8.62 | 8.62 - 8.65 |
| Low: | 7.92 - 7.95 | 7.95 - 7.99 |
| Close: | 8.17 - 8.22 | 8.22 - 8.27 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Mon, 17 Nov 2025
ALGS: PEVY/PhosCovir shows best-in-class HBV suppression and safety, with pivotal data expected in 2027 - TradingView
Fri, 14 Nov 2025
Aligos Therapeutics (ALGS) Awards Stock Options as Inducement Gr - GuruFocus
Fri, 14 Nov 2025
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fri, 14 Nov 2025
Aligos (NASDAQ: ALGS) grants 23,600-share inducement options under Nasdaq Rule 5635(c)(4) - Stock Titan
Mon, 10 Nov 2025
Aligos Therapeutics (ALGS) Showcases Promising Data at AASLD 202 - GuruFocus
Tue, 04 Nov 2025
Aligos Therapeutics Inc expected to post a loss of $1.90 a share - Earnings Preview - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3e+006 (%) |
| Held by Institutions | 10.3 (%) |
| Shares Short | 273 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.582e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 827.3 % |
| Return on Equity (ttm) | -54.8 % |
| Qtrly Rev. Growth | 2.65e+006 % |
| Gross Profit (p.s.) | -15.08 |
| Sales Per Share | -51.39 |
| EBITDA (p.s.) | -2.38406e+007 |
| Qtrly Earnings Growth | -13.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -79 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.17 |
| Price to Cash Flow | 1.94 |
| Dividend | 0 |
| Forward Dividend | 227280 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|